Cancer treatment and research communications最新文献

{"title":"Characteristics, incidence, and survival of unknown stage cancer: A US population-based study","authors":"Ray M. Merrill,&nbsp;Alida J. Johnson","doi":"10.1016/j.ctarc.2025.100949","DOIUrl":"10.1016/j.ctarc.2025.100949","url":null,"abstract":"<div><h3>Introduction</h3><div>This study examines the extent of unknown stage cancer incidence for 24 cancer sites in the U.S. based on reporting source, selected variables, and cancer lethality.</div></div><div><h3>Methods</h3><div>Analyses included 5,447,023 malignant cancer cases diagnosed during 2015–2021, collected by 22 population-based cancer registries in the Surveillance, Epidemiology, and End Results (SEER) Program. Poisson regression estimated adjusted rate ratios.</div></div><div><h3>Results</h3><div>Approximately 9.4 % of males and 7.2 % of females had unstaged cancer, significantly varying by reporting source. Levels of unstaged cancer identified by hospital, physician, or other; autopsy; death certificate; or nursing/convalescent home/hospice were 7.8 %, 32.6 %, 97.0 %, and 82.0 % in males and 5.8 %, 31.2 %, 97.1 %, and 82.4 % in females, respectively. Rates increased with age when the reporting source was hospital, physician, or other but decreased with age for autopsy, death certificate, or nursing/convalescence home/hospice. Unstaged cancer rates were similar between men and women (<em>r</em> = 0.93, <em>p</em> &lt; 0.0001, not including breast cancer). However, men were seen to have a 60 % higher rate of unstaged cancer (95 % CI 59 %-61 %) compared to women. Rates increased with age, decreased with income, and were 11 % (95 % CI 10 %-12 %) higher in Blacks (vs. Whites), and 11 % (95 % CI 10 %-12 %) higher in Hispanics (vs. non-Hispanics). A significant negative association was found between unstaged cancer percentages and 5-year relative survival rates for both sexes.</div></div><div><h3>Conclusions</h3><div>Males, older age, Blacks, Hispanics, and lower income patients are more susceptible to not receiving a cancer stage because of higher comorbid illness, more aggressive cancer, and less ability to pay for treatment.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100949"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144196427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of first-line pemetrexed plus carboplatin followed by pemetrexed maintenance in newly diagnosed and metastatic elderly non-squamous Non-Small Cell Lung Cancer (NSCLC): Real World Data (RWD) of a Galician and Mediterranean lung cancer group","authors":"Arias Ron David ,&nbsp;Álvarez Fernández Javier ,&nbsp;García Benito Carme ,&nbsp;Huidobro Vence Gerardo ,&nbsp;García Lorenzo Carme ,&nbsp;Santomé Couto Lucía ,&nbsp;Amenedo Gancedo Margarita ,&nbsp;Esquerdo Galiana Gaspar ,&nbsp;Areses Manrique María Carmen ,&nbsp;Fernández Núñez Natalia ,&nbsp;Lázaro Quintela Martín ,&nbsp;Casal Rubio Joaquín ,&nbsp;Afonso Afonso Francisco Javier ,&nbsp;Campos Balea Begoña ,&nbsp;García Mata Jesús ,&nbsp;Aversa Caterina ,&nbsp;Vázquez Estévez Sergio ,&nbsp;Fírvida Pérez Jose Luis","doi":"10.1016/j.ctarc.2025.100960","DOIUrl":"10.1016/j.ctarc.2025.100960","url":null,"abstract":"<div><h3>Background</h3><div>The role of Pemetrexed combined with platinum chemotherapy in newly diagnosed and metastatic non-squamous NSCLC is clearly defined since the results of Paramount trial. Currently, platinum chemotherapy plus immunotherapy has become the gold standard treatment in most of patients. Elderly patients are usually underrepresented in clinical trials and there is a lack of data in this setting. We analysed the efficacy and safety of platinum-pemetrexed chemotherapy in a cohort of newly diagnosed and metastatic elderly non-squamous NSCLC patients.</div></div><div><h3>Patients and methods</h3><div>In this multicentre, retrospective, real-world cohort, we collected all newly diagnosed and metastatic non-squamous NSCLC aged ≥70 years and treated with carboplatin-pemetrexed chemotherapy followed by pemetrexed maintenance. Patients characteristics, comorbidities and mutational status were described. Our objective is to analyse the efficacy and safety of doublet regimen in an elderly cohort.</div></div><div><h3>Results</h3><div>67 patients were included in the analysis. Median age was 75 years (70–84), mostly of them showed Performance status (PS) 1 (79 %) and 36 % presented with extrapulmonary metastases. 52 % of patients presented at least three comorbidities. Median PFS was 5.3 months (CI 95 % 4–6.6, <em>p</em> = 0.66) while median OS was 9.7 months (CI 95 % 8.3–11.1, <em>p</em> = 0.72). Fatigue (14 %) and neutropenia (12 %) were the most common grade 3–4 Adverse Event (AE), while asthenia (64 %) was the most common grade 1–2 AE.</div></div><div><h3>Conclusion</h3><div>Pemetrexed-based chemotherapy followed by pemetrexed maintenance is efficacious and safe in newly diagnosed and metastatic non-squamous NSCLC patients aged ≥70 years, achieving similar results in terms of survival and toxicity than pivotal trials. So, this doublet regimen may be considered as an alternative in patients who are not candidate for triplet regimen with platinum chemotherapy plus Immune Checkpoint Inhibitors (ICIs) or they don´t have access for them.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100960"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144842204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer","authors":"Chikako Funasaka ,&nbsp;Takahiro Kogawa ,&nbsp;Naoya Sakamoto ,&nbsp;Shota Kusuhara ,&nbsp;Takehiro Nakao ,&nbsp;Hiromichi Nakajima ,&nbsp;Chihiro Kondoh ,&nbsp;Kenichi Harano ,&nbsp;Nobuaki Matsubara ,&nbsp;Ako Hosono ,&nbsp;Yoichi Naito ,&nbsp;Mototsugu Shimokawa ,&nbsp;Rurina Watanuki ,&nbsp;Yuji Yamashita ,&nbsp;Chisako Yamauchi ,&nbsp;Tatsuya Onishi ,&nbsp;Genichiro Ishii ,&nbsp;Toru Mukohara","doi":"10.1016/j.ctarc.2025.100941","DOIUrl":"10.1016/j.ctarc.2025.100941","url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) is a highly aggressive subtype of BC. A pathological complete response (pCR) to neoadjuvant chemotherapy is strongly associated with a favorable TNBC prognosis; however, established predictors of pCR, including tumor-infiltrating lymphocytes (TILs), are often not adequately reliable in the clinic. This study evaluated the utility of immunohistochemistry (IHC)-based markers and TILs in predicting pCR in early-stage TNBC. This study enrolled 61 women with stage I–III TNBC who were treated at our institution between January 2013 and December 2019. Pathological data were collected from electronic medical records, while IHC data were obtained from preoperative biopsy specimens. Fisher’s test, multivariable logistic regression, and correlation analyses were used to identify biomarker candidates and their interactions. The majority of the patients had stage II or III invasive ductal TNBC. The pCR rate was 31 % (19/61). High TIL frequencies (≥ 40 %) and high Ki-67 (≥ 40 %) levels were associated with pCR. Among the patients with high TIL frequencies, AR-negative patients had a higher pCR rate than AR-positive patients (55.0 % versus 16.7 %; <em>p</em> = 0.71). Vimentin negativity correlated with high TIL frequencies (<em>p</em> = 0.02). High TIL frequencies and high Ki-67 levels were independently associated with an increased likelihood of achieving a pCR. The combination of high TIL frequencies and high Ki-67 levels was predictive of pCR in patients with primary TNBC, while AR and vimentin represent candidate markers that require further validation. Further studies should evaluate the performance of these markers in combination with other biomarkers and in the context of immune-checkpoint blockade.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100941"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological description of genetic alterations and prognosis in Mexican patients with melanoma: a retrospective cohort","authors":"Katia F. Ávila-Fernández ,&nbsp;Héctor Martínez-Said ,&nbsp;Ivan R. González-Espinoza ,&nbsp;Rodrigo R. Flores-Mariñelarena ,&nbsp;Gabriela Juárez-Salazar ,&nbsp;Mariana Chiquillo-Dominguéz ,&nbsp;Abraham Castro-Ponce ,&nbsp;Julio C. Garibay-Díaz ,&nbsp;Jerónimo R. Rodríguez-Cid","doi":"10.1016/j.ctarc.2025.100973","DOIUrl":"10.1016/j.ctarc.2025.100973","url":null,"abstract":"<div><h3>Background</h3><div>Melanoma is currently the most aggressive skin cancer. It is currently categorized based on mutations that have been studied for their prognostic relevance.</div></div><div><h3>Objective</h3><div>Define the epidemiology of mutations in patients with melanoma in Mexico using the Next-Generation Sequencing technology and explore its prognosis utility in terms of prognosis.</div></div><div><h3>Methods</h3><div>A descriptive, multicentric, analytical, and retrospective study was conducted on sixteen patients with melanoma and NGS.</div></div><div><h3>Results</h3><div>Sixteen patients with nodular, lentiginous acral melanoma, and superficial extension were included. We found sixteen different mutations in the melanoma samples. The most frequent mutation in our population was the BRAF mutation (56.3 %); the CCND1 and NRAS mutations were found in 18.8 %. There was a statistically significant association between NRAS and mortality. Median progression-free survival was 27 months (95 % CI = 6.5–47.42 months) and median overall survival was 40.18 months (95 % CI = 19.03 – 61.3 months). The frequency of the mutations we found is similar to the ones reported in the literature, except for CD274, ROS1, and CDKN2A/B, which are more common in our population. We only found a prognostic value with NRAS, even though there is some evidence of mortality associated with other mutations.</div></div><div><h3>Conclusion</h3><div>NGS is a useful tool that can detect multiple mutations in the same patient. Detecting profiles with prognostic values and mutations for targeted therapy is an option for these patients, however, the usefulness of these results must be further studied in larger cohorts.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100973"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of Image-guided Tru-cut biopsy in the diagnosis of breast tumors","authors":"Alya A. Al Zobair ,&nbsp;Wahda M. Al-Nauimy ,&nbsp;Sabruldeen M. Mohammed","doi":"10.1016/j.ctarc.2025.100955","DOIUrl":"10.1016/j.ctarc.2025.100955","url":null,"abstract":"<div><h3>Background</h3><div>Histopathological examination is the gold standard for the diagnosis of breast cancer. This study aims to ascertain the extent to which image-guided Tru-cut biopsy is sensitive and accurate in the diagnosis of breast cancer cases in our locality.</div></div><div><h3>Method</h3><div>This prospective study included 115 patients who presented with one or more breast lumps and suspected to be neoplastic based on the clinical and radiological assessment. All patients have been subjected to Tru-cut biopsy under ultrasound guidance to confirm or exclude the diagnosis of breast tumor, the study was conducted between January 2022 and January 2024</div></div><div><h3>Result</h3><div>Tru-cut biopsy under ultrasound-guidance has shown a high sensitivity and specificity, 98 % and 100 % respectively. Breast carcinoma was confirmed in 106 cases, while benign breast lesions were diagnosed in the remaining nine cases.</div></div><div><h3>Conclusion</h3><div>A Tru-cut biopsy of palpable breast tumors yields comprehensive information with a high sensitivity and specificity, making it a highly reliable diagnostic tool for breast tumors.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100955"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144331121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic literature review of MTAP deletions in solid and hematologic Cancers","authors":"Mary C. Clouser ,&nbsp;Mina Suh ,&nbsp;Naimisha Movva ,&nbsp;Janet S. Hildebrand ,&nbsp;Susan T. Pastula ,&nbsp;Martina Schoehl ,&nbsp;Antreas Hindoyan ,&nbsp;Akhila Balasubramanian ,&nbsp;Jon P. Fryzek ,&nbsp;Soo-Ryum Yang","doi":"10.1016/j.ctarc.2025.100966","DOIUrl":"10.1016/j.ctarc.2025.100966","url":null,"abstract":"<div><h3>Background</h3><div>Methylthioadenosine phosphorylase (<em>MTAP)</em> deficiency is observed across multiple cancers and represents an emerging biomarker with therapeutic potential via synthetic lethality with PRMT5 inhibition. This systematic literature review summarizes the prevalence of <em>MTAP</em> deletions or loss of expression and prognostic impacts of <em>MTAP</em> deletions or loss in adult and pediatric patients with specific solid or hematologic cancers.</div></div><div><h3>Methods</h3><div>Following PRISMA methodology, the literature on <em>MTAP</em> deletion or loss in multiple cancer types was reviewed. Prevalence, laboratory testing methods, patient characteristics, and clinical outcomes according to <em>MTAP</em> status were synthesized. Study quality was determined using standard tools.</div></div><div><h3>Results</h3><div>Of the 352 identified studies, 37 reported on <em>MTAP</em>. The majority were retrospective cohorts (N=32; 86%). The most common laboratory test type was NGS, specifically FoundationOne (N=7, 24%). <em>MTAP</em> deletion (loss) prevalence varied across tumor types and were generally lowest in gastric cancer (4%–14%) and highest in glioblastoma (26%–60%). <em>MTAP</em> deletion was correlated with higher prevalence of <em>KRAS</em>. Variation by age, gender, and race/ethnicity were inconsistently reported. Survival outcomes were reported most often for GBM and NSCLC with some studies suggesting worse overall survival among patients with <em>MTAP</em> deletions, although the evidence was heterogeneous.</div></div><div><h3>Conclusion</h3><div>This is the first systematic review to summarize the literature on <em>MTAP</em> deletions or loss of expression across several solid and hematologic cancers. <em>MTAP</em> deletions and/or loss of expression occur in many cancer types, presenting a promising target for pan-cancer therapy.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100966"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144713197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy","authors":"Rolando J. Acosta ,&nbsp;Debra A.G. McIntyre ,&nbsp;Joseph C. Murray ,&nbsp;Valsamo Anagnostou ,&nbsp;Julie R Brahmer ,&nbsp;Alexander Meisel ,&nbsp;Ahmet Sezer ,&nbsp;Miranda Gogishvili ,&nbsp;Tamar Melkadze ,&nbsp;Ana Baramidze ,&nbsp;Tamta Makharadze ,&nbsp;Adam Y. He ,&nbsp;Vladimir Jankovic ,&nbsp;Gregory P. Geba ,&nbsp;Asha Pillai ,&nbsp;Frank Seebach ,&nbsp;Petra Rietschel ,&nbsp;Giuseppe Gullo ,&nbsp;Jean-Francois Pouliot ,&nbsp;Young Kim","doi":"10.1016/j.ctarc.2025.100959","DOIUrl":"10.1016/j.ctarc.2025.100959","url":null,"abstract":"<div><h3>Background</h3><div>Patients with a high neutrophil/lymphocyte ratio (NLR) have poor prognosis in non-small cell lung cancer (NSCLC). Limited data are available on the contribution of other immune cells. This analysis assessed the prognostic importance of NLR and other peripheral blood cells in patients with advanced NSCLC receiving the PD-1 inhibitor cemiplimab in 2 large phase III studies.</div></div><div><h3>Methods</h3><div>The impact of baseline immune cells on survival was assessed in patients with complete blood cell counts. Cox proportional hazard regression and Kaplan–Meier methods assessed the relationships between baseline blood cell counts and survival. Data were randomly split into training (70 %) and validation (30 %) cohorts to allow for independent evaluation of the Cox model.</div></div><div><h3>Results</h3><div>Multivariable analyses revealed that a higher NLR (HR: 1.09; 95 % CI: 1.06–1.12, <em>P</em> &lt; .001) and monocytes (HR: 1.49; 95 % CI: 1.15–1.93, <em>P</em> &lt; .001) were strongly associated with an increased risk of death. Higher levels of eosinophils (HR: 0.93; 95 % CI: 0.88–0.99, <em>P</em> &lt; .001) were associated with a reduced risk of death. A calibration curve of observed and predicted probabilities in the unseen test set using independent data revealed that the Cox model was well-calibrated up to a 1-year mortality probability of approximately 30 %. Harrell’s concordance index was 0.61, indicating a modest predictive performance.</div></div><div><h3>Conclusions</h3><div>Our data confirmed the detrimental impact of a high NLR on survival and revealed the importance of monocyte levels in anti-tumor responses, providing useful information to physicians treating advanced NSCLC that may help tailor immunotherapy regimens and provide more accurate prognostic assessments.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100959"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144678839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of adjuvant therapy on survival in treatment of CNS hemangiopericytomas","authors":"Bharti Devnani ,&nbsp;Subhash Gupta ,&nbsp;Vibhay Pareek ,&nbsp;Ahitagni Biswas ,&nbsp;Haresh KP ,&nbsp;Manmohan Singh ,&nbsp;Vivek Tandon ,&nbsp;Ashish Suri ,&nbsp;Pramod Kumar Julka ,&nbsp;Goura Kishor Rath","doi":"10.1016/j.ctarc.2025.100982","DOIUrl":"10.1016/j.ctarc.2025.100982","url":null,"abstract":"<div><h3>Introduction</h3><div>Central nervous system (CNS) Hemangiopericytoma is a rare tumor which account for &lt;0.5% of all CNS tumors. The purpose of this study was to assess the clinical outcomes and the impact of adjuvant treatment on survival.</div></div><div><h3>Materials/ Methods</h3><div>A total of 64 patients histo-pathologically diagnosed as CNS Hemangiopericytoma, treated between 2000 and 2018 with or without adjuvant radiation and chemotherapy, were evaluated for the various survival parameters. Kaplan Meier method was utilized for assessment of the survival outcomes. Treatment and demographic parameters were assessed as prognostic factors for the survival outcomes using Multivariate analysis. The patients were followed up as per the institution protocol.</div></div><div><h3>Results</h3><div>The median follow-up was 50.6 months (range: 8–158 months). The median age was 40 years (range: 8–63 years), with 44 male and 20 female patients. Headache was the most common symptom (46 patients, 71.8%), followed by visual disturbances (18 patients, 28.1%). Tumors were primarily supratentorial (50 patients, 78.1%), with a median diameter of 5 cm (range: 2–7.6 cm). Gross total resection (GTR) was achieved in 40 patients (62.5%). Of the cohort, 34 patients (53.1%) had WHO grade II tumors, and 30 (46.9%) had grade III tumors. Radiation therapy was administered to 54 patients (84.4%) with a median dose of 60 Gy (range: 40–60 Gy), and 8 patients (12.5%) received stereotactic radiation therapy (median: 16.1 Gy). Adjuvant chemotherapy (ifosfamide and epirubicin-based) was given to 40 patients (62.5%). Recurrence occurred in 31 patients (48.4%), with 24 patients (37.5%) experiencing local recurrence and 7 patients (10.9%) developing distant metastases. The median recurrence-free survival (RFS) was 38.4 months, and the median overall survival (OS) was 44 months. Multivariate analysis showed that radiation therapy (<em>p</em> = 0.012), chemotherapy (<em>p</em> &lt; 0.001), and GTR (<em>p</em> = 0.023) significantly reduced recurrence risk.</div></div><div><h3>Conclusion</h3><div>Even though CNS Hemangiopericytoma is a rare disease entity, local and distant recurrences are a cause of concern and require evaluation of role of adjuvant therapy. Our study shows that complete excision followed by adjuvant therapy in the form of radiation therapy and chemotherapy improves the survival in CNS Hemangiopericytoma. Besides the prognostic factors assessed, there is a need for larger prospective study to improve the treatment outcomes.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"45 ","pages":"Article 100982"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145057364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of hypoxia on extracellular vesicles in malignant and non-malignant conditions","authors":"Vahid Niazi ,&nbsp;Soudeh Ghafouri-Fard","doi":"10.1016/j.ctarc.2025.100924","DOIUrl":"10.1016/j.ctarc.2025.100924","url":null,"abstract":"<div><div>Extracellular vesicles (EVs) are produced by virtually all types of cells and can be detected in nearly all extracellular places. These particles mediate intercellular communication and transfer their cargo to the recipient cells, inducing a variety of processes in these cells through transmission of several biomolecules such as miRNAs, lncRNAs, other transcripts and a variety of proteins. It has been documented that size, quantity, and expression of biomolecules in the EVs are influenced by the level of oxygen. In fact, hypoxia can affect several cellular processes through modulation of the cargo of these vesicles. Hypoxic exosomes derived from tumor cells have several protumoral effects on the recipient cells, including enhancement of proliferation, migration, and invasion in other tumoral cells, induction of metastasis in distant organs, stimulation of angiogenesis in the endothelial cells, and modulation of macrophage polarization. Hypoxic EVs also contribute to several non-malignant diseases. This review summarizes the effect of hypoxia on EVs cargo in malignant and nonmalignant diseases of different organs.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100924"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143799159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"At-home autologous hematopoietic cell transplant for adults with hematological malignancies. How frailty impacts and evolves during HCT procedure. An observational, longitudinal, and prospective study","authors":"Juan Ortiz ,&nbsp;María Teresa Solano ,&nbsp;Cristina Gallego ,&nbsp;Nuria Ballestar ,&nbsp;Noemi de Llobet ,&nbsp;Laia Guardia ,&nbsp;Raquel Salinas ,&nbsp;Alexandra Martínez-Roca ,&nbsp;Beatriz Merchán ,&nbsp;Paola Charry ,&nbsp;Joan Cid ,&nbsp;Miquel Lozano ,&nbsp;Enric Carreras ,&nbsp;Sara Laxe ,&nbsp;Concepción Closa ,&nbsp;María Suárez-Lledó ,&nbsp;Laura Rosiñol ,&nbsp;Carmen Martínez ,&nbsp;Montserrat Rovira ,&nbsp;Francesc Fernández-Avilés ,&nbsp;María Queralt Salas","doi":"10.1016/j.ctarc.2025.100920","DOIUrl":"10.1016/j.ctarc.2025.100920","url":null,"abstract":"<div><h3>Introduction and aims</h3><div>Since April 2021, the frailty state of patients is evaluated routinely in adults undergoing auto-HCT at our institution using the HCT Frailty Scale. The scale categorises each candidate as either fit, pre-fit or frail.</div></div><div><h3>Methods</h3><div>Our study includes 80 consecutive adults with lymphoprolipherative disorders (LPD) and multiple myeloma (MM) undergoing at-home auto-HCT at our institution between June 2021 and June 2023. An initial evaluation of frailty was conducted at first consultation (pre-apheresis), followed by a subsequent evaluation at day +100.</div></div><div><h3>Results</h3><div>The median age was 58 years (range: 19–69), 41 (51.2 %) patients were males, 45 (56.3 %) were diagnosed with MM and 35 with LPD. At the initial consultation, 24 (30.0 %) adults were classified as fit, 48 (60.0 %) as pre-frail, and 8 (10.0 %) as frail. Frail patients were more likely to be older (OR 1.16 <em>P</em> = 0.077), and to have a KPS &lt; 90 % (OR 27, <em>P</em> = 0.012), and also exhibit a higher number of comorbidities (HCT-CI&gt;3: OR 11.9, <em>p</em> = 0.035). However, the underlying diagnosis did not impact the incidence of frailty at the initial consultation (OR 0.99, <em>p</em> = 0.999).</div></div><div><h3>Conclusions</h3><div>There was no association between the duration of at-home transplant hospitalisation and readmissions and the presence of frailty syndrome. Moreover, no patient died due to transplant-related toxicity. The results presented in this study support that at-home auto-HCT can be performed in fit, pre-frail, and frail adults with an experienced and multidisciplinary team. Although conclusions are limited by the reduced sample size, the observed differences on frailty incidences during patient's follow-up support that frailty is dynamic, and potentially amendable with specific interventions.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100920"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143816380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}